Abstract
299 patients with stage III or IV Hodgkin's disease were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). The complete remission rates (59.9% for MOPP, 59.4% for LOPP), actuarial survival (65.7 and 68.2% at 5 years, respectively) and complete remission/relapse free survival (33.3 and 32.2% at 5 years, respectively) were similar for both groups. There were no significant differences in response data between the MOPP and LOPP groups for individual prognostic variables (histology grade, stage, age and response to treatment). Deaths in both groups were usually due to disseminated Hodgkin's disease with terminal infection; there were no infective deaths in the absence of Hodgkin's disease. The less toxic regimen of LOPP can therefore be expected to produce results similar to those seen with MOPP, and this is true regardless of the severity of the illness.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
